Search results for " Percutaneous"

showing 10 items of 55 documents

Excimer laser technology in percutaneous coronary interventions: Cardiovascular laser society's position paper

2022

Excimer Laser Coronary Atherectomy (ELCA) is a well-established therapy that emerged for the treatment of peripheral vascular atherosclerosis in the late 1980s, at a time when catheters and materials were rudimentary and associated with the most serious complications. Refinements in catheter technology and the introduction of improved laser techniques have led to their effective use for the treatment of a wide spectrum of complex coronary lesions, such as thrombotic lesions, severe calcific lesions, non-crossable or non-expandable lesions, chronic occlusions, and stent under-expansion. The gradual introduction of high-energy strategies combined with the contrast infusion technique has enabl…

Chronic occlusionAtherectomy CoronaryTechnologyAtherectomySevere calcific lesionChronic occlusions; ELCA; Laser angioplasty; Severe calcific lesions; Stent under-expansion; Thrombotic lesions; Coronary Angiography; Humans; Lasers Excimer; Technology; Treatment Outcome; Atherectomy Coronary; Percutaneous Coronary InterventionLasersCoronaryThrombotic lesionCoronary AngiographyChronic occlusionsExcimerTreatment OutcomePercutaneous Coronary InterventionStent under-expansionSevere calcific lesionsHumansLaser angioplastyLasers ExcimerELCACardiology and Cardiovascular MedicineThrombotic lesionsHumanInternational Journal of Cardiology
researchProduct

Behavior of patients at high risk of developing contrast induced nephropathy after coronary procedures

2012

Contrast induced nephropathy atherosclerosis percutaneous coronary intervention coronary angiography
researchProduct

Decrease in annual incidence of acute coronary syndrome and restructuring of coronary care in Latvia

2014

Abstract Introduction Improvement in coronary heart disease prevention and treatment, as well as availability of coronary care facilities, is important for the reduction of acute coronary syndrome (ACS) incidence. Centralized acute coronary care system is crucial to provide optimal hospitalization and management algorithm for ACS patients. Aim The aim of the current report was to assess the annual incidence of ACS and the quality of acute coronary care in Latvia. Methods The Data from The Latvian Registry of Acute Coronary Syndromes were analyzed covering the time period from 2005 to 2010. Results Since the year 2005 the annual incidence of hospitalization due to ACS decreased significantly…

Emergency medical servicesmedicine.medical_specialtyAcute coronary syndromeInvasive strategybusiness.industryIncidence (epidemiology)medicine.medical_treatmentPrimary percutaneous coronary interventionPercutaneous coronary interventionmedicine.diseaseAnnual incidenceManagement algorithmEmergency medicinemedicineEmergency medical servicesRegistry dataAcute coronary syndromeIntensive care medicinebusinessCardiology and Cardiovascular MedicineCor et Vasa
researchProduct

PERCUTANEOUS US (ULTRA SOUND) GUIDED FINE NEEDLE ASPIRATION (FNA) OF ENDOTHORACIC NEOPLASM

2022

Introduction: Ultrasound (US)-guided fine needle aspiration (FNA) of percutaneous, transparietal endothoracic lesions, is a useful method in the diagnostic process for anatomopathological characterization. This sampling is a minimally invasive procedure, with a low complication rate and can be performed under loco-regional anesthesia Material and methods: We retrospectively studied (2009 to 2019) the utility of US guided transthoracic FNA in the diagnosis of suspected endothoracic lesions on 54 patients (34 men and 20 women), aged between 44 and 79 years, with pleural, pulmonary or mediastinal neoplasm viewable with an US examination. Results: The definitive diagnosis of malignant or benign…

Fine needle aspiration (FNA) Percutaneous Ultrasound (US)-guided
researchProduct

Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)

2017

IF 3.398; International audience; The prognosis of patients with acute myocardial infarction (AMI) has notably improved in the past 20 years. Using the French Registry of ST-Elevation and Non-ST-elevation Myocardial Infarction (FAST-MI) 2010 registry, we investigated whether previous manifestations of atherosclerotic disease (i.e., previous MI, or a history of any form of atherosclerotic disease) are at truly increased risk compared with those in whom AMI is the first manifestation of the disease. FAST-MI 2010 is a nationwide French registry including 3,079 patients with AMI, among whom 1,062 patients had a history of cardiovascular atherosclerotic disease and 498 patients had a history of …

MaleMESH : Atherosclerosismedicine.medical_treatmentMESH : MortalityMyocardial InfarctionMESH : AgedMESH : Prospective StudiesAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDiseaseMESH : Cerebrovascular Disorders0302 clinical medicineMedicineLongitudinal StudiesProspective StudiesMESH: Coronary Artery DiseaseMyocardial infarctionCoronary Artery BypassMESH: Treatment OutcomeCause of deathAged 80 and overeducation.field_of_studyMESH: Middle AgedHazard ratioMESH : Platelet Aggregation InhibitorsPrognosisMESH: Case-Control Studies3. Good healthMESH: Myocardial InfarctionMESH: Angiotensin Receptor AntagonistsMESH : Angiotensin-Converting Enzyme InhibitorsCardiology and Cardiovascular MedicineMESH: Percutaneous Coronary InterventionMESH : Case-Control Studiesmedicine.medical_specialtyMESH : Angiotensin Receptor AntagonistsMESH: Prognosis03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedMESH : Coronary Artery DiseaseMESH : Aged 80 and overMESH: Hydroxymethylglutaryl-CoA Reductase InhibitorseducationMESH: Age DistributionAgedMESH: HumansMESH: MortalityProportional hazards modelMESH: Coronary Artery BypassMESH : HumansCase-control studyMESH : Proportional Hazards Modelsmedicine.diseaseMESH : Coronary Artery BypassCase-Control StudiesMESH: FemaleMESH: RegistriesMESH : Age Distribution030204 cardiovascular system & hematologyMESH: AtherosclerosisMESH: Proportional Hazards ModelsMESH: Cause of DeathMESH: Aged 80 and overMESH : Percutaneous Coronary InterventionRisk FactorsMESH: Risk FactorsCause of DeathMESH : FemaleRegistries030212 general & internal medicineMESH: Longitudinal StudiesMESH : Longitudinal StudiesMESH: AgedMESH : PrognosisMESH: Angiotensin-Converting Enzyme InhibitorsMESH: Adrenergic beta-AntagonistsMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsTreatment OutcomeMESH: Platelet Aggregation InhibitorsCardiologyFemaleMESH: Cerebrovascular DisordersFranceMESH : MaleAdrenergic beta-AntagonistsMESH : Adrenergic beta-AntagonistsPopulationMESH : Treatment OutcomeMESH: Multivariate AnalysisAngiotensin Receptor AntagonistsAge DistributionInternal medicineMortalityMESH : FranceProportional Hazards ModelsMESH : Cause of Deathbusiness.industryMESH : Hydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Multivariate AnalysisPercutaneous coronary interventionAtherosclerosisMESH: MaleMESH: Prospective StudiesMESH: FranceCerebrovascular DisordersMultivariate AnalysisHydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Myocardial InfarctionbusinessPlatelet Aggregation InhibitorsMESH : RegistriesThe American Journal of Cardiology
researchProduct

ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in France.

2021

Systems of care have been challenged to control progression of the COVID-19 pandemic. Whether this has been associated with delayed reperfusion and worse outcomes in French patients with ST-segment elevation myocardial infarction (STEMI) is unknown.Aim: To compare the rate of STEMI admissions, treatment delays, and outcomes between the first peak of the COVID-19 pandemic in France and the equivalent period in 2019.Methods: In this nationwide French survey, data from consecutive STEMI patients from 65 centres referred for urgent revascularization between 1 March and 31 May 2020, and between 1 March and 31 May 2019, were analysed. The primary outcome was a composite of in-hospital death or no…

MaleMESH: Hyperlipidemiasmedicine.medical_treatmentMESH: ComorbidityComorbidity030204 cardiovascular system & hematologyMESH: Health Care SurveysMESH: HypertensionMESH: Procedures and Techniques Utilization0302 clinical medicinePatient AdmissionInterquartile rangeMESH: Risk FactorsRisk FactorsST segmentMESH: COVID-19030212 general & internal medicineMyocardial infarctionHospital MortalityMESH: Treatment Outcomeeducation.field_of_studyMESH: Middle AgedCardiogenic shockSmokingMESH: Patient Acceptance of Health CareGeneral MedicineMESH: Heart Rupture Post-InfarctionMiddle AgedPrognosis[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTreatment OutcomeHypertensionCardiologyFemaleStentsFranceCardiology and Cardiovascular MedicineSCA ST+MESH: Percutaneous Coronary Interventionmedicine.medical_specialtyMESH: PandemicsMESH: SmokingMESH: Diabetes MellitusPopulationComplications mécaniquesHyperlipidemiasRevascularizationMESH: PrognosisTime-to-TreatmentSTEMI03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineLockdownmedicineDiabetes MellitusHumansMESH: SARS-CoV-2MESH: Time-to-TreatmentMESH: Hospital MortalityMESH: ST Elevation Myocardial InfarctioneducationPandemicsHeart Rupture Post-InfarctionMESH: Humansbusiness.industryMESH: Patient AdmissionSARS-CoV-2Percutaneous coronary interventionCOVID-19Patient Acceptance of Health Caremedicine.diseaseComorbidityMESH: MaleMESH: FranceMESH: Stents[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHealth Care SurveysST Elevation Myocardial Infarction[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMechanical complicationsbusinessMESH: FemaleProcedures and Techniques UtilizationConfinementArchives of cardiovascular diseases
researchProduct

Treatment of stages IIIIV of the Dupuytrens Disease using a personal approach: percutaneous needle fasciotomy (PNF) and minimal invasive selective ap…

2013

Abstract The authors present their experience in treating 23 fingers on 20 patients affected by Dupuytrens Disease in stages III and IV of the Tubiana classification with their personal technique that involves the percutaneous needle fasciotomy followed 40 days after by a selective open aponeurectomy on the previously treated cord, by making a small cutaneous incision. The treatment requires careful selection of the patients. In fact, patients suffering from the disease for more than 5 years and all the cases with a suspicion of joint rigidity are excluded from the study. The average follow up period was approximately 48 months. 18 out of the 20 patients had excellent functional recovery. S…

MaleSettore MED/19 - Chirurgia PlasticaFasciotomyDupuytren ContractureTendonsTreatment OutcomeNeedlesaponeurectomy Dupuytren percutaneous needle fasciotomy stage III and IVHumansMinimally Invasive Surgical ProceduresFemaleOrthopedic ProceduresAgedFollow-Up StudiesRetrospective StudiesActa chirurgiae plasticae
researchProduct

CT-guided nephrostomy–An expedient tool for complex clinical scenarios

2018

Abstract Introduction & objectives Percutaneous nephrostomy [ 1 ] has emerged as a pivotal approach in the therapeutic management of the obstructed urinary tract. A consecutive incorporation of ultrasonic and radiographic guidance, the approach experienced an almost ubiquitious distribution while most centers currently applying either one or both of these tools jointly. However, success of ultrasound-guidance is limited in obese patients and non-dilated uropathy. In turn, fluoroscopy usually requires an opacification of the urinary collecting system by intravenous or antegrade contrast media injection, which might be harmful for already impaired renal function, raise intrapelvic pressure an…

MaleUrologic Diseasesmedicine.medical_specialtySupine positionUrinary systemmedicine.medical_treatmentKidneyRadiography Interventional030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineUrethral DiseasesmedicineHumansRadiology Nuclear Medicine and imagingObesityRenal InsufficiencyObstructive uropathyUltrasonography InterventionalAgedNephrostomy PercutaneousRetrospective Studiesbusiness.industryMortality rateGeneral MedicineOverweightmedicine.diseaseSurgeryProne positionSurgery Computer-AssistedPercutaneous nephrostomyFluoroscopy030220 oncology & carcinogenesisFeasibility StudiesFemaleMedian bodyTomography X-Ray ComputedbusinessComplicationAnesthesia LocalDilatation PathologicEuropean Journal of Radiology
researchProduct

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes

2013

Item does not contain fulltext BACKGROUND: Although P2Y12 antagonists are effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes, the effect of the timing of administration--before or after coronary angiography--is not known. We evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated. METHODS: We enrolled 4033 patients with NSTE acute coronary syndromes and a positive troponin level who were scheduled to undergo coronary angiography within 2 to 48 hours after randomization. Patients were randomly assigned to recei…

Malemedicine.medical_specialtyAcute coronary syndromePrasugrelmedicine.medical_treatmentPremedicationMyocardial InfarctionHemorrhageThiophenesCoronary AngiographyPiperazinesPercutaneous Coronary InterventionDouble-Blind MethodInternal medicinemedicineHumansMyocardial infarctionAcute Coronary SyndromeCoronary Artery BypassAgedCardiovascular diseases [NCEBP 14]business.industryMedicine (all)Hazard ratioAcute Coronary Syndrome; Aged; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Coronary Angiography; Premedication; Medicine (all)Percutaneous coronary interventionGeneral MedicineThrombolysisMiddle Agedta3121medicine.diseaseConventional PCICardiologyPurinergic P2Y Receptor AntagonistsFemalebusinessPrasugrel HydrochlorideTIMImedicine.drug
researchProduct

Contrast-induced Nephropathy after Percutaneous Coronary Intervention in Simple Lesions: Risk Factors and Incidence are Affected by the Definition Ut…

2011

Aim To compare the incidence, and risk factors, in-hospital and at the 18-month prognosis of contrast-induced nephropathy (CIN) according to the definition utilized: as an increase in serum creatinine (Scr) ≥0.5 mg/dL (CIN 1) or as an increase in Scr ≥25% above baseline values (CIN 2). Methods and Results We prospectively evaluated CIN according to two different definitions in 150 patients who underwent percutaneous coronary intervention (PCI) in simple lesions employing a low-medium dose of contrast media. Incidence of CIN was higher using the CIN 2 definition than CIN 1 (9.3% vs. 4%; p=0.0133). Patients with CIN 1 had a higher incidence of chronic kidney disease (CKD) (66.7% vs. 13.9%; p=…

Malemedicine.medical_specialtyAnemiamedicine.medical_treatmentContrast-induced nephropathyUrologyContrast MediaRenal functionurologic and male genital diseasesPercutaneous coronary interventionNephropathychemistry.chemical_compoundContrast induced nephropathyRisk FactorsInternal MedicinemedicineHumansProspective StudiesAngioplasty Balloon CoronaryRenal Insufficiency ChronicneoplasmsAgedCreatininecontrast induced nephropathy percutaneous coronary interventionbusiness.industryIncidenceIncidence (epidemiology)virus diseasesPercutaneous coronary interventionAnemiaGeneral MedicineMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsSurgerysurgical procedures operativeItalychemistryCreatinineFemaleKidney DiseasesbusinessKidney diseaseInternal Medicine
researchProduct